ONE-TWENTY TWO: Trading Financial Markets
Exploring the poetry in financial markets for students of money and economy since the year 2000.
Morgan Stanley (MS) initiated coverage on Intercept Pharmaceuticals, Inc. (ICPT) with an underweight rating. The negativity weighed on the stock for a 7.9% loss that sent the stock below critical support at its 200-day moving average (DMA). Source: FreeStockCharts.com Morgan was VERY emphatic about its “out of consensus” call on ICPT. As reported by Investors.com: … Read more
(T2108 measures the percentage of stocks trading above their respective 40-day moving averages [DMAs]. It helps to identify extremes in market sentiment that are likely to reverse. To learn more about it, see my T2108 Resource Page. You can follow real-time T2108 commentary on twitter using the #T2108 hashtag. T2108-related trades and other trades are … Read more
(T2108 measures the percentage of stocks trading above their respective 40-day moving averages [DMAs]. It helps to identify extremes in market sentiment that are likely to reverse. To learn more about it, see my T2108 Resource Page. You can follow real-time T2108 commentary on twitter using the #T2108 hashtag. T2108-related trades and other trades are … Read more
After the market closed for trading on January 29, 2015, Intercept Pharmaceuticals (ICPT) released exciting news: ICPT’s “…investigational product obeticholic acid (OCA) has received “breakthrough therapy designation” from the U.S. Food and Drug Administration (FDA) for the treatment of patients with nonalcoholic steatohepatitis (NASH) with liver fibrosis. This indication constitutes a population of patients with … Read more
(T2108 measures the percentage of stocks trading above their respective 40-day moving averages [DMAs]. It helps to identify extremes in market sentiment that are likely to reverse. To learn more about it, see my T2108 Resource Page. You can follow real-time T2108 commentary on twitter using the #T2108 hashtag. T2108-related trades and other trades are … Read more
Intercept Pharmaceuticals, Inc. (ICPT) may indeed have the $5B blockbluster liver drug that RBC Capital Markets claimed in hiking its price target on the stock from $425 to $500. Gilead (GILD) may indeed buy out the company. Other analysts like Leerink Partners who raised its price target from $270 to $445, and Deutsche Bank who … Read more
(T2108 measures the percentage of stocks trading above their respective 40-day moving averages [DMAs]. It helps to identify extremes in market sentiment that are likely to reverse. To learn more about it, see my T2108 Resource Page. You can follow real-time T2108 commentary on twitter using the #T2108 hashtag. T2108-related trades and other trades are … Read more